Abstract
Yang et al.1 reported on reduced-dose rituximab treatment in NMO. To demonstrate the efficacy of rituximab, it is critical to show the relationship between the clinical response and B-cell depletion. Low-dose rituximab requires greater vigilance than conventional dosages, and appropriate monitoring is essential. However, the irregular B-cell monitoring (sometimes greater than 15 weeks) in this study is inadequate for determining the B-cell kinetics following low-dose rituximab. Consequently, the infusions were often administered after the reconstitution of B cells (greater than 3.5%) and exceeded the therapeutic target (greater than 1%). No relapse occurred despite marked reconstitution of B cells. Perhaps the result is not just a treatment effect but largely related to …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
